Vincent Vandamme - Orgenesis VP Strategy

ORGSDelisted Stock  USD 1.22  0.31  20.26%   

Insider

Vincent Vandamme is VP Strategy of Orgenesis
Phone480 659 6404
Webhttps://orgenesis.com

Orgenesis Management Efficiency

The company has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2725) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.
Orgenesis currently holds 22.62 M in liabilities with Debt to Equity (D/E) ratio of 0.64, which is about average as compared to similar companies. Orgenesis has a current ratio of 1.54, which is within standard range for the sector. Debt can assist Orgenesis until it has trouble settling it off, either with new capital or with free cash flow. So, Orgenesis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orgenesis sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orgenesis to invest in growth at high rates of return. When we think about Orgenesis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

JD EsqTango Therapeutics
54
Alan HuangTango Therapeutics
51
Fangyong DuAdagene
54
Levi MDTango Therapeutics
55
Michael AlleyAN2 Therapeutics
N/A
Eric EasomAN2 Therapeutics
56
Brian MDRezolute
49
Jc MDAdagene
59
MD MBARezolute
N/A
Eric DevroeAcrivon Therapeutics, Common
45
Sergio QuezadaAchilles Therapeutics PLC
49
MD BAPasithea Therapeutics Corp
76
Michael NewmanIndaptus Therapeutics
68
Guizhong LiuAdagene
53
Dawn GiangiulioDesign Therapeutics
N/A
Kristina MassonAcrivon Therapeutics, Common
44
Antoni MDTango Therapeutics
57
Donna DeaAerovate Therapeutics
N/A
Rasmus HolmJorgensenAcrivon Therapeutics, Common
52
Denise CarterQuoin Pharmaceuticals Ltd
55
MBA BSAN2 Therapeutics
49
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people. Orgenesis [ORGS] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Orgenesis Leadership Team

Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Victor Miller, Chief Officer
Osher Rheinisch, General Officer
Neil CPA, S CFO
Shimon Hassin, Chief Officer
Efrat Kunik, Chief Officer
Pierre Lammeretz, Interim Officer
Evan Fishman, Chief Officer
Joseph Carpinelli, Chief Octomera
Dan Slonim, COO Israel
Vered MSc, CEO Board
Pr Ferber, Founder Officer
Vincent Vandamme, VP Strategy

Orgenesis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.
Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in Orgenesis OTC Stock

If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.